Summary: A key finding in the origins of lupus has been discovered. In those with systemic lupus erythematosus, B cells are abnormally activated. This results in the production of antibodies which react against the patient’s own tissue, causing a range of symptoms including rashes, joint pain, and fatigue.
Source: Emory University
New research on the autoimmune disease systemic lupus erythematosus (SLE) provides hints to the origins of the puzzling disorder. The results were published Monday in Nature Immunology.
In people with SLE, their B cells – part of the immune system – are abnormally activated. That makes them produce antibodies that react against their own tissues, causing a variety of symptoms, such as fatigue, joint pain, skin rashes, and kidney problems.
Scientists at Emory University School of Medicine could discern that in people with SLE, signals driving expansion and activation are present at an earlier stage of B cell differentiation than previously appreciated. They identified patterns of gene activity that could be used as biomarkers for disease development.
“Our data indicate a disease signature across all cell subsets, and importantly on mature resting B cells, suggesting that such cells may have been exposed to disease-inducing signals,” the authors write.
The paper reflects a collaboration between the laboratories of Jeremy Boss, PhD, chairman of microbiology and immunology, and Ignacio (Iñaki) Sanz, MD, head of the division of rheumatology in the Department of Medicine. Sanz, recipient of the 2019 Lupus Insight Prize from the Lupus Research Alliance, is director of the Lowance Center for Human Immunology and a Georgia Research Alliance Eminent Scholar. The first author is Christopher Scharer, PhD, assistant professor of microbiology and immunology.
The researchers studied blood samples from 9 African American women with SLE and 12 healthy controls. They first sorted the B cells into subsets, and then looked at the DNA in the women’s B cells, analyzing the patterns of gene activity. Sanz’s team had previously observed that people with SLE have an expansion of “activated naïve” and DN2 B cells, especially during flares, periods when their symptoms are worse.
By examining epigenetic parameters – inherited traits not encoded in the DNA sequence — and patterns of gene activity, the researchers could see signs of activation in “resting naïve” B cells, which precede the activated naïve cells. They were able to surmise that resting naïve cells are being stimulated through particular receptor pathways. This “provides an important window to understand early antigenic triggers,” the authors write. The authors were also able to identify regulatory networks that drive the disease phenotype in SLE B cells. Together, these their results open up new avenues for future investigation and therapeutic interventions.
Funding: The research was supported by the National Institute of Allergy and Infectious Diseases (U19AI110483, P01AI125180, RO1AI113021, F31AI112261) and the National Institute of General Medical Sciences (T32GM008490).
Source:
Emory University
Media Contacts:
Quinn Eastman – Emory University
Image Source:
The image is credited to Emory University.
Original Research: Closed access
“Epigenetic programming underpins B cell dysfunction in human SLE”. Christopher D. Scharer, Emily L. Blalock, Tian Mi, Benjamin G. Barwick, Scott A. Jenks, Tsuneo Deguchi, Kevin S. Cashman, Bridget E. Neary, Dillon G. Patterson, Sakeenah L. Hicks, Arezou Khosroshahi, F. Eun-Hyung Lee, Chungwen Wei, Iñaki Sanz & Jeremy M. Bos.
Nature Immunology. doi:10.1038/s41590-019-0419-9
Abstract
Epigenetic programming underpins B cell dysfunction in human SLE
Systemic lupus erythematosus (SLE) is characterized by the expansion of extrafollicular pathogenic B cells derived from newly activated naive cells. Although these cells express distinct markers, their epigenetic architecture and how it contributes to SLE remain poorly understood. To address this, we determined the DNA methylomes, chromatin accessibility profiles and transcriptomes from five human B cell subsets, including a newly defined effector B cell subset, from subjects with SLE and healthy controls. Our data define a differentiation hierarchy for the subsets and elucidate the epigenetic and transcriptional differences between effector and memory B cells. Importantly, an SLE molecular signature was already established in resting naive cells and was dominated by enrichment of accessible chromatin in motifs for AP-1 and EGR transcription factors. Together, these factors acted in synergy with T-BET to shape the epigenome of expanded SLE effector B cell subsets. Thus, our data define the molecular foundation of pathogenic B cell dysfunction in SLE.
